logo
Share SHARE
FONT-SIZE Plus   Neg

Sodexo H1 Group Profit Rises - Quick Facts

Sodexo (SDXAY.PK) said its first-half group net income was up to 297 million euros from 252 million euros last year.

Consolidated revenues grew 9.7% year-over-year to 9.07 billion euros, reflecting solid organic growth of 6.4%, a 3.9% increase related to acquisitions and changes in consolidation scope, and a negative currency impact of 0.6%.

Commenting on the results, CEO Michel Landel said,

"Our first half results are solid, demonstrating the relevance of Sodexo's strategy and Quality of Life services offer, illustrated by the major contract wins of the past several months. Organic growth is increasing, driven by development of more than 10% in our Facilities Management services and in our Motivation Solutions activity.

In a tough economic environment, our teams are fully mobilized to provide clients the innovation and productivity they expect.

We are maintaining our full year Fiscal 2012 objectives of an increase of around 10% in operating profit based on organic revenue growth of between 6% and 7%, with acquisitions also impacting revenues by around 4%."

In the medium term, Sodexo confirmed its objective of achieving annual average consolidated revenue growth of 7% and targets a consolidated operating margin of 6.3% for the end of fiscal 2015.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of International Consolidated Airlines Group S.A. were gaining around 3 percent in London trading after the airline reported Friday higher profit in its second quarter, benefited by higher passenger revenues, despite weak cargo revenues. The company now expects low double digit percentage growth in pre-exceptional operating profit in 2016. Swiss banking giant UBS Group AG reported Friday a 14 percent decline in second quarter profit with weakness in net interest income. Looking ahead, the company said the difficult conditions continue to persist, yet the firm is well positioned to benefit from even a moderate improvement in conditions. UBS shares were gaining around 3 percent in the morning trading in Zurich. We are well into the third quarter and past the middle of the year and it is time to take stock of regulatory decisions awaiting some biotech stocks in August. Despite the uncertain macroeconomic environment, the markets have run up, with the S&P 500 Index making new highs session after session. Valuation concerns may keep traders at bay. However, the biotech space is a different cup of tea.
comments powered by Disqus
Follow RTT